data
postop
chylou
ascit
ca
pediatr
liver
transplant
lt
scarc
retrospect
studi
conduct
identifi
incid
risk
factor
manag
outcom
postop
ca
larg
singlecent
pediatr
lt
cohort
studi
cohort
compris
lt
live
donor
deceas
donor
recipi
median
age
year
incid
ca
n
diagnos
median
time
day
lt
compar
chylomicron
detect
periton
fluid
gold
standard
triglycerid
cutoff
valu
mgdl
periton
fluid
show
insuffici
sensit
ca
diagnosi
univari
logist
regress
analys
ascit
lt
younger
age
lower
weight
height
heightforag
z
score
lt
associ
ca
symptomat
manag
ca
includ
periton
drain
diuret
therapeut
intervent
includ
lowfat
mediumchain
triglyceriderich
diet
intraven
octreotid
lead
ca
resolut
patient
ca
associ
prolong
hospit
length
stay
lo
day
ca
group
versu
day
nonca
group
p
reduc
patient
graft
surviv
rate
median
followup
time
year
conclus
ca
pediatr
lt
recipi
rel
uncommon
complic
associ
increas
hospit
lo
morbid
measur
chylomicron
recommend
patient
ascit
sever
persist
expect
dietari
intervent
effect
patient
abnorm
hepat
venou
outflow
obstruct
smallfors
syndrom
abdomin
infect
second
diagnost
criteria
ca
well
establish
detect
chylomicron
lipoprotein
electrophoresi
periton
fluid
consid
gold
standard
diagnost
test
avail
triglycerid
cutoff
mgdl
mmoll
periton
fluid
recommend
pediatr
lt
literatur
latter
recommend
support
highqual
evid
recogn
triglycerid
quantif
periton
fluid
may
reliabl
diagnost
criterion
ca
fast
patient
particularli
postop
state
recent
gap
literatur
address
accept
triglycerid
cutoff
valu
mgdl
mmoll
establish
diagnosi
ca
optim
manag
postop
ca
unclear
one
studi
pediatr
lt
recipi
report
dietari
therapi
effect
anoth
advoc
use
pharmacolog
therapi
firstlin
therapi
highvolum
output
chylou
leakag
mlkgday
studi
aim
determin
incid
risk
factor
treatment
outcom
postop
ca
larg
pediatr
lt
cohort
use
detect
chylomicron
gold
standard
diagnost
test
newli
establish
triglycerid
cutoff
patient
method
patient
popul
casecontrol
studi
includ
children
younger
year
old
underw
lt
surgeri
hospit
sick
children
toronto
ontario
canada
januari
decemb
infant
children
receiv
organ
addit
liver
transplant
outsid
institut
ca
diagnos
prior
lt
exclud
lt
recipi
experienc
graft
loss
death
within
day
follow
lt
also
exclud
data
retriev
prospect
popul
electron
databas
retrospect
chart
review
data
captur
patient
risk
analysi
outcom
report
includ
demograph
primari
diagnosi
pretranspl
comorbid
surgic
data
periop
morbid
vascular
thrombosi
biliari
complic
longterm
outcom
retransplant
death
height
weight
z
score
calcul
use
world
health
organ
growth
standard
addit
data
collect
patient
ca
includ
inform
regard
diagnosi
manag
outcom
ca
studi
patient
follow
institut
protocol
immunosuppress
receiv
either
standard
induct
corticosteroid
calcineurin
inhibitor
tacrolimu
renalneurotoxicspar
protocol
corticosteroid
either
antithymocyt
globulin
dose
basiliximab
simulect
novarti
basel
switzerland
delay
introduct
calcineurin
inhibitor
agent
studi
receiv
approv
institut
research
ethic
board
hospit
sick
children
ascit
prior
lt
defin
presenc
moderatetolarg
amount
periton
fluid
abdomin
ultrasound
histori
diuret
use
treatment
ascit
prior
lt
posttranspl
ca
defin
presenc
chylomicron
triglycerid
valu
mgdl
mmoll
periton
fluid
within
day
lt
absenc
posit
periton
fluid
cultur
triglycerid
valu
mgdl
mmoll
periton
fluid
consid
equivoc
diagnosi
ca
posttransplant
hospit
length
stay
lo
defin
interv
day
transplant
day
first
discharg
hospit
data
express
mean
standard
deviat
median
interquartil
rang
iqr
origin
articl
nonnorm
distribut
data
identifi
student
test
use
continu
variabl
nonparametr
test
mannwhitney
u
test
use
continu
variabl
abnorm
distribut
identifi
chisquar
test
fisher
exact
test
employ
categor
variabl
incid
ca
calcul
togeth
confid
interv
ci
limit
patient
surviv
rate
estim
kaplanmei
method
compar
logrank
test
logist
regress
univari
analys
perform
explor
associ
ca
variabl
clinic
signific
statist
analys
perform
spss
version
spss
inc
chicago
il
p
valu
consid
statist
signific
studi
cohort
assembl
summar
fig
final
studi
cohort
compris
isol
lt
perform
pediatr
patient
median
age
lt
year
iqr
year
median
weight
lt
kg
iqr
kg
median
followup
time
whole
cohort
year
iqr
year
live
donor
deceas
donor
whole
liver
reduc
split
graft
indic
lt
includ
biliari
atresia
alagil
syndrom
cholestat
liver
diseas
metabol
diseas
acut
liver
failur
malign
total
patient
postop
ca
identifi
give
incid
ci
tabl
summar
demograph
diseasespecif
data
lt
recipi
without
ca
age
weight
height
lt
significantli
lower
lt
recipi
ca
compar
nonca
group
p
group
compar
respect
sex
underli
diagnosi
liver
graft
type
incid
postop
hepat
arteri
thrombosi
portal
vein
thrombosi
within
first
month
lt
show
statist
differ
ca
nonca
group
two
case
bile
leak
diagnos
treat
laparotomi
prior
ca
diagnosi
although
trend
toward
higher
bile
leak
note
ca
group
reach
statist
signific
ca
group
versu
nonca
group
versu
p
incid
ca
per
surgeon
oper
studi
period
similar
p
actuari
patient
surviv
patient
without
ca
respect
compar
respect
patient
ca
p
fig
actuari
graft
surviv
fig
patient
without
ca
respect
compar
respect
patient
ca
p
univari
analys
ascit
transplant
identifi
signific
risk
factor
develop
ca
lt
odd
ratio
young
age
transplant
per
year
lower
weight
transplant
per
kg
lower
height
transplant
per
cm
lower
heightforag
z
score
lt
surrog
marker
nutrit
statu
also
associ
develop
ca
tabl
median
time
diagnosi
ca
day
iqr
day
lt
surgeri
day
iqr
day
postop
start
enter
feed
patient
surgic
drain
place
time
diagnosi
fluid
test
result
obtain
paracentesi
n
vacuumassist
closur
vac
devic
n
also
patient
develop
pleural
effus
requir
drainag
patient
chyle
detect
pleural
fluid
tabl
provid
detail
patient
develop
postop
ca
within
day
lt
diagnosi
ca
biochem
evid
chylomicron
detect
patient
triglycerid
mgdl
mmoll
patient
test
chylomicron
chylomicron
detect
triglycerid
mgdl
mmoll
remain
patient
triglycerid
level
periton
fluid
measur
patient
ca
triglycerid
valu
diagnost
cutoff
valu
patient
within
equivoc
rang
ca
diagnosi
patient
equivoc
rang
patient
white
cell
count
periton
fluid
cellsmm
case
analyz
median
cell
count
cellsmm
iqr
cellsmm
lymphocyt
predomin
lymphocyt
percentag
patient
neg
periton
fluid
cultur
time
ca
diagnosi
periton
drain
use
patient
ca
symptomat
manag
ascit
median
durat
ca
diagnosi
time
drain
remov
day
iqr
day
patient
drain
day
drain
reinsert
remov
requir
patient
total
patient
receiv
diuret
dietari
modif
use
children
includ
lowfat
diet
patient
abl
take
solid
food
mouth
lowfat
formula
tolerex
tabl
biopsyproven
liver
allograft
acut
cellular
reject
defin
reject
activ
index
accord
banff
schema
rang
diagnos
patient
within
first
postop
day
pod
sever
lymphopenia
l
note
lt
recipi
ca
within
month
lt
lymphopenia
resolv
patient
except
patient
resolut
could
confirm
transfer
anoth
institut
death
children
postop
ca
receiv
treatment
document
infect
follow
diagnosi
ca
within
month
lt
cytomegaloviru
cmv
viremia
n
urinari
tract
infect
enterococcu
spp
n
periton
periton
drain
remain
situ
enterobact
spp
n
upper
respiratori
tract
infect
parainfluenza
type
n
pneumonia
coronaviru
n
children
ca
group
except
transfer
anoth
institut
receiv
palli
care
discharg
home
median
day
iqr
day
within
day
discharg
patient
rehospit
pneumonia
biopsyproven
liver
allograft
acut
cellular
reject
also
death
occur
ca
group
due
posttranspl
recurr
hepatoblastoma
hemophagocyt
lymphohistiocytosi
month
lt
respect
find
larg
pediatr
cohort
reveal
postop
ca
uncommon
complic
children
lt
lead
prolong
hospit
lo
immedi
postop
morbid
impact
longterm
graft
patient
surviv
case
earli
recognit
ca
symptomat
manag
ascit
use
periton
drain
dietari
intervent
mctrich
formulaveri
lowfat
dietnpo
tpn
respons
formula
led
resolut
ca
patient
receiv
pharmacolog
therapi
incid
ca
studi
popul
similar
valu
report
mix
pediatr
adult
studi
adult
studi
yet
recent
studi
describ
seri
pediatr
lt
report
ca
incid
reason
incid
discrep
unclear
probabl
relat
differ
practic
around
surgic
drain
insert
periton
fluid
test
rate
surgic
drain
insert
lower
studi
compar
report
marseglia
et
al
addit
studi
patient
investig
chylomicron
periton
fluid
rais
possibl
symptomat
ca
diagnos
cohort
similar
incid
cohort
develop
ascit
prior
transplant
sign
decompens
cirrhosi
associ
higher
risk
develop
ca
lymphangiogenesi
describ
context
cirrhosi
specul
may
help
accommod
increas
lymphat
flow
elev
portal
pressur
possibl
increas
lymphat
circul
patient
cirrhosi
contribut
increas
risk
traumat
ca
lt
howev
evid
support
hypothesi
lack
find
keep
report
yilmaz
et
al
also
identifi
develop
ascit
prior
lt
independ
risk
factor
ca
nonetheless
smaller
studi
report
children
young
adult
lt
recipi
postop
ca
similar
rate
ascit
pretranspl
radiolog
imag
without
ca
main
differ
studi
lie
time
identif
ascit
anytim
preoper
latter
without
clear
whether
lt
recipi
first
studi
previous
develop
ascit
analysi
yield
addit
risk
factor
develop
postop
ca
name
age
year
weight
kg
time
transplant
find
may
relat
smaller
calib
vascular
lymphat
structur
younger
children
put
small
children
greater
risk
traumat
injuri
lymphat
vessel
surgeri
similarli
lower
heightforag
z
score
lt
gener
impli
failur
thrive
malnutrit
also
significantli
associ
higher
risk
postop
ca
result
support
report
describ
pretranspl
malnutrit
children
risk
factor
posttranspl
morbid
given
weightforag
z
score
may
underestim
degre
undernutrit
children
chronic
liver
diseas
effect
organomegali
andor
ascit
surpris
associ
found
weightforag
z
score
lt
postop
ca
concurr
initi
enter
feed
postop
ca
manifest
primarili
persist
ascit
milki
drainag
surgic
drain
situ
often
set
otherwis
adequ
graft
function
ca
integr
part
differenti
diagnosi
earli
ascit
transplant
addit
common
postop
complic
hepat
arteri
portal
venou
abnorm
hepat
venou
outflow
obstruct
smallfors
syndrom
abdomin
infect
suspicion
ca
prompt
investig
confirm
diagnosi
detect
chylomicron
periton
fluid
obtain
either
periton
drain
paracentesi
consid
gold
standard
test
diagnosi
ca
recent
triglycerid
cutoff
mgdl
mmoll
periton
fluid
suggest
addit
diagnost
tool
ca
studi
lt
recipi
ca
nonca
group
respect
investig
chylomicron
triglycerid
periton
fluid
found
recent
propos
triglycerid
cutoff
insuffici
sensit
diagnost
tool
find
suggest
triglycerid
cutoff
may
reliabl
criterion
exclud
diagnosi
ca
fast
partial
fed
pediatr
lt
recipi
maldonado
et
al
report
similar
find
determin
biochem
paramet
chylou
pleural
fluid
patient
chylothorax
particularli
fast
postop
state
periton
fluid
also
sent
cell
count
lymphocyt
predomin
cultur
neg
lack
consensu
regard
optim
manag
postop
ca
treatment
origin
articl
option
rang
nutrit
intervent
pharmacolog
treatment
surgic
procedur
contrast
group
report
seri
reli
symptomat
manag
ascit
diuret
andor
insert
periton
drain
nutrit
intervent
manag
ca
larg
periton
drain
loss
gener
replac
intraven
albumin
ratio
less
drain
clamp
fluid
output
mlkgday
reach
seri
abdomin
infect
bacteri
periton
occur
patient
easili
manag
nutrit
intervent
use
patient
includ
dietari
fat
modif
children
dietari
fat
modif
plu
period
fast
parenter
nutrit
patient
dietari
fat
modif
fail
diminish
periton
drain
loss
patient
follow
fatfre
mctrich
diet
fat
sourc
length
time
may
need
supplement
essenti
fatti
acid
efa
fatsolubl
vitamin
therefor
given
potenti
efa
defici
patient
follow
dietari
fat
modif
implement
empir
supplement
veget
oil
contrast
recommend
group
pharmacolog
therapi
somatostatin
analogu
octreotid
use
patient
nutrit
strategi
fail
reduc
chylou
leakag
volum
consid
octreotid
markedli
reduc
splanchnic
blood
flow
also
potenti
caus
liver
injuri
believ
nutrit
intervent
safer
treatment
option
octreotid
limit
bias
studi
relat
retrospect
natur
data
collect
incomplet
respect
interpret
clinic
judgment
rational
clinic
care
decis
given
low
incid
ca
report
studi
prospect
control
studi
determin
efficaci
therapeut
option
manag
ca
would
difficult
conduct
children
strength
studi
includ
use
gold
standard
diagnost
test
chylomicron
detect
rel
larg
pediatr
sampl
size
wide
rang
pediatr
age
underli
diagnos
surgic
techniqu
summari
present
comprehens
analysi
incid
risk
factor
outcom
manag
strategi
postop
ca
pediatr
lt
recipi
although
ca
lt
rel
uncommon
associ
prolong
hospit
lo
immedi
postop
morbid
ca
sought
children
increas
periton
drain
loss
ascit
lt
particularli
younger
popul
histori
ascit
malnutrit
lt
chylomicron
detect
periton
fluid
appear
sensit
test
overran
arbitrari
triglycerid
cutoff
valu
children
undergo
lt
symptomat
manag
ca
periton
drain
dietari
intervent
highli
effect
firstlin
treatment
modal
major
patient
routin
use
octreotid
recommend
requir
earli
recognit
treatment
unusu
complic
shorten
hospit
lo
reduc
degre
postop
morbid
